# A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

> **NCT06567782** · PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 120 (estimated)

## Conditions studied

- Neoplasms, Colon

## Interventions

- **BIOLOGICAL:** Dostarlimab
- **DRUG:** CAPEOX

## Key facts

- **NCT ID:** NCT06567782
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2026-11-23
- **Final completion:** 2028-10-26
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06567782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06567782, "A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06567782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*